Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02349178 · ClinicalTrials.gov registry record · Phase 2
Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02349178 is a Phase 2 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 6 participants.
The verdict
NCT02349178, a Phase 2 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a Phase 2 study designed for the purpose of estimating various parameters surrounding the efficacy of Clofarabine, Cyclophosphamide and Etoposide in eliminating minimal residual disease (MRD) in acute leukemia patients otherwise in remission and without causing significant delay of HCT due to treatment related toxicity. A single course of "bridge" chemotherapy is given prior to the transplant procedure as an approach to improved disease-free survival in a patient group who historically has had inferior outcomes.
Interventions
- DRUG Cyclophosphamide
- DRUG Etoposide
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-12-08 |
| Est. Completion | 2017-03-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02349178
The ClinicalTrials.gov registry entry for NCT02349178 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02349178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02349178 about?
NCT02349178 is a clinical study titled "Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT". This is a Phase 2 study designed for the purpose of estimating various parameters surrounding the efficacy of Clofarabine, Cyclophosphamide and Etoposide in eliminating minimal residual disease (MRD) in acute leukemia patients otherwise in remission and without causing significant delay of HCT due t...
What is the current status of trial NCT02349178?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2014-12-08. Estimated completion is 2017-03-16.
What interventions are being tested in trial NCT02349178?
The interventions under investigation include: Cyclophosphamide (DRUG), Etoposide (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT02349178?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.